Charles River Laboratories International (CRL) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Charles River Laboratories International (CRL) has outperformed Incyte (INCY) over the past year, gaining 71.8% versus a gain of 32.1%. Over five years, INCY leads with a +72.0% price change compared with -26.2% for CRL. Incyte is the larger company by market cap ($22.85 billion vs $14.35 billion), about 1.6 times the size.
On valuation, Incyte trades at a lower forward P/E (12.9x vs 23.3x for Charles River Laboratories International). Incyte converts more of its revenue into profit, with a net margin of 25.0% versus -3.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRL | INCY |
|---|---|---|
| Share price | $298.00 | $112.75 |
| Market cap | $14.35B | $22.85B |
| 1-day change | -0.77% | -0.61% |
| YTD return | +49.39% | +14.15% |
| 1-year return | +71.79% | +32.06% |
| 5-year return | -26.15% | +71.98% |
| P/E ratio (TTM) | — | 14.36 |
| Forward P/E | 23.33 | 12.89 |
| EPS (TTM) | $-4.80 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.02B | $5.14B |
| Revenue growth (YoY) | -0.85% | +21.22% |
| Net income (latest FY) | $-144.34M | $1.29B |
| Gross margin | — | 92.76% |
| Operating margin | 0.63% | 29.46% |
| Net margin | -3.59% | 25.03% |
| 52-week high | $333.30 | $132.60 |
| 52-week low | $146.20 | $82.82 |
| Distance from 52-week high | -10.59% | -14.97% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +2.35% | +14.53% |
| Average volume | 956.13K | 1.63M |
| Shares outstanding | 48.17M | 202.70M |
| Employees | 18,300 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRL has outperformed INCY by 39.7 percentage points over the past year.
- Incyte is more profitable, keeping 25.0 cents of every revenue dollar as net income versus -3.6 cents for Charles River Laboratories International.
- Incyte grew revenue faster in its latest fiscal year (+21.22% vs -0.85%).
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
CRL vs INCY FAQ
Which is bigger, Charles River Laboratories International or Incyte?
Incyte (INCY) is larger, with a market capitalization of $22.85B compared with $14.35B for Charles River Laboratories International (CRL).
Which stock has performed better over the past year, CRL or INCY?
CRL returned +71.79% over the past 12 months, compared with +32.06% for INCY (price return, excluding dividends). Past performance does not predict future results.
Are Charles River Laboratories International and Incyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.